Inhibiting BTK in Chronic Lymphocytic Leukemia

N Engl J Med. 2023 Jul 6;389(1):83-86. doi: 10.1056/NEJMe2302721.

Authors

Arnon P Kater¹, Barbara Eichhorst¹

Affiliation

¹ From the Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (A.P.K.); and Department I of Internal Medicine and Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, University of Cologne, Cologne, Germany (B.E.).

PMID: 37407007
DOI: 10.1056/NEJMe2302721

No abstract available

Publication types

Editorial

MeSH terms

Agammaglobulinaemia Tyrosine Kinase / genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
Protein Kinase Inhibitors* / pharmacology
Protein Kinase Inhibitors* / therapeutic use
Protein-Tyrosine Kinases / genetics

Substances

Agammaglobulinaemia Tyrosine Kinase
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
BTK protein, human